Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2013 by University of Catania
Sponsor:
Information provided by (Responsible Party):
Mariano Malaguarnera, University of Catania
ClinicalTrials.gov Identifier:
NCT01921192
First received: August 8, 2013
Last updated: NA
Last verified: August 2013
History: No changes posted
  Purpose

Homocysteine, a well-known inducer of vascular endothelial cell damage has been associated with extracellular matrix changes. Many studies demonstrated that high levels of this aminoacid in diabetic patients increases significantly the risk of the development of this pathology. This study has been undertaken to investigate the role of homocysteine and its cofactors (folic acid, vitamin B6 and B12) during the progression of the diabetic retinopathy.


Condition Intervention Phase
Non Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Drug: Folic Acid, vit B6 and B12
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by University of Catania:

Primary Outcome Measures:
  • homocysteine [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • folic acid [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]

Other Outcome Measures:
  • vitamin B6 [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • vitamin B12 [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 160
Study Start Date: September 2012
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Folic Acid, vit B6 and B12 Drug: Folic Acid, vit B6 and B12
Placebo Comparator: Sugar pill Drug: Placebo

  Eligibility

Ages Eligible for Study:   40 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • diabetic patients with proliferative and non proliferative retinopathy

Exclusion Criteria:

  • Patients with chronic liver disease Patients with kidney disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01921192

Contacts
Contact: Mariano Malaguarnera, A.P. +39(0)957262008 malaguar@unict.it

Locations
Italy
University of Catania, Cannizzaro Hospital Recruiting
Catania, Italy, 95125
Sponsors and Collaborators
University of Catania
  More Information

No publications provided

Responsible Party: Mariano Malaguarnera, Associate Professor, University of Catania
ClinicalTrials.gov Identifier: NCT01921192     History of Changes
Other Study ID Numbers: 1/2012
Study First Received: August 8, 2013
Last Updated: August 8, 2013
Health Authority: Italy: Ethics Committee

Additional relevant MeSH terms:
Diabetic Retinopathy
Retinal Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Diabetic Angiopathies
Endocrine System Diseases
Eye Diseases
Vascular Diseases
Folic Acid
Vitamin B Complex
Growth Substances
Hematinics
Hematologic Agents
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vitamins

ClinicalTrials.gov processed this record on November 27, 2014